Cargando…

Previous BCG vaccination is associated with less severe clinical progression of COVID-19

BACKGROUND: BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is associated with less severe clinical progression of COVID-19 METHODS: A case-cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Susan Martins, Barreto, Florisneide Rodrigues, de Souza, Ramon Andrade, de Souza Teles Santos, Carlos Antonio, Pereira, Marcos, da Paixão, Enny Santos, de Jesus Lima, Carla Cristina Oliveira, da Natividade, Marcio Santos, Lindoso, Ana Angélica Bulcão Portela, Fernandes, Eder Gatti, Junior, Evonio Barros Campelo, Pescarini, Julia Moreira, de Andrade, Kaio Vinicius Freitas, de Souza, Fernanda Mattos, de Britto, Elisangela Alves, Nunes, Ceuci, Ichihara, Maria Yuri, Dalcolmo, Margareth, Trajman, Anete, Barral-Netto, Manoel, Abubakar, Ibrahim, Barreto, Mauricio Lima, de Alencar Ximenes, Ricardo Arraes, Rodrigues, Laura Cunha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099006/
https://www.ncbi.nlm.nih.gov/pubmed/37055776
http://dx.doi.org/10.1186/s12916-023-02859-x
_version_ 1785024953191497728
author Pereira, Susan Martins
Barreto, Florisneide Rodrigues
de Souza, Ramon Andrade
de Souza Teles Santos, Carlos Antonio
Pereira, Marcos
da Paixão, Enny Santos
de Jesus Lima, Carla Cristina Oliveira
da Natividade, Marcio Santos
Lindoso, Ana Angélica Bulcão Portela
Fernandes, Eder Gatti
Junior, Evonio Barros Campelo
Pescarini, Julia Moreira
de Andrade, Kaio Vinicius Freitas
de Souza, Fernanda Mattos
de Britto, Elisangela Alves
Nunes, Ceuci
Ichihara, Maria Yuri
Dalcolmo, Margareth
Trajman, Anete
Barral-Netto, Manoel
Abubakar, Ibrahim
Barreto, Mauricio Lima
de Alencar Ximenes, Ricardo Arraes
Rodrigues, Laura Cunha
author_facet Pereira, Susan Martins
Barreto, Florisneide Rodrigues
de Souza, Ramon Andrade
de Souza Teles Santos, Carlos Antonio
Pereira, Marcos
da Paixão, Enny Santos
de Jesus Lima, Carla Cristina Oliveira
da Natividade, Marcio Santos
Lindoso, Ana Angélica Bulcão Portela
Fernandes, Eder Gatti
Junior, Evonio Barros Campelo
Pescarini, Julia Moreira
de Andrade, Kaio Vinicius Freitas
de Souza, Fernanda Mattos
de Britto, Elisangela Alves
Nunes, Ceuci
Ichihara, Maria Yuri
Dalcolmo, Margareth
Trajman, Anete
Barral-Netto, Manoel
Abubakar, Ibrahim
Barreto, Mauricio Lima
de Alencar Ximenes, Ricardo Arraes
Rodrigues, Laura Cunha
author_sort Pereira, Susan Martins
collection PubMed
description BACKGROUND: BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is associated with less severe clinical progression of COVID-19 METHODS: A case-control study comparing the proportion with a BCG vaccine scar (indicating previous vaccination) in cases and controls presenting with COVID-19 to health units in Brazil. Cases were subjects with severe COVID-19 (O2 saturation < 90%, severe respiratory effort, severe pneumonia, severe acute respiratory syndrome, sepsis, and septic shock). Controls had COVID-19 not meeting the definition of “severe” above. Unconditional regression was used to estimate vaccine protection against clinical progression to severe disease, with strict control for age, comorbidity, sex, educational level, race/colour, and municipality. Internal matching and conditional regression were used for sensitivity analysis. RESULTS: BCG was associated with high protection against COVID-19 clinical progression, over 87% (95% CI 74–93%) in subjects aged 60 or less and 35% (95% CI − 44–71%) in older subjects. CONCLUSIONS: This protection may be relevant for public health in settings where COVID-19 vaccine coverage is still low and may have implications for research to identify vaccine candidates for COVID-19 that are broadly protective against mortality from future variants. Further research into the immunomodulatory effects of BCG may inform COVID-19 therapeutic research.
format Online
Article
Text
id pubmed-10099006
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100990062023-04-14 Previous BCG vaccination is associated with less severe clinical progression of COVID-19 Pereira, Susan Martins Barreto, Florisneide Rodrigues de Souza, Ramon Andrade de Souza Teles Santos, Carlos Antonio Pereira, Marcos da Paixão, Enny Santos de Jesus Lima, Carla Cristina Oliveira da Natividade, Marcio Santos Lindoso, Ana Angélica Bulcão Portela Fernandes, Eder Gatti Junior, Evonio Barros Campelo Pescarini, Julia Moreira de Andrade, Kaio Vinicius Freitas de Souza, Fernanda Mattos de Britto, Elisangela Alves Nunes, Ceuci Ichihara, Maria Yuri Dalcolmo, Margareth Trajman, Anete Barral-Netto, Manoel Abubakar, Ibrahim Barreto, Mauricio Lima de Alencar Ximenes, Ricardo Arraes Rodrigues, Laura Cunha BMC Med Research Article BACKGROUND: BCG vaccination, originally used to prevent tuberculosis, is known to “train” the immune system to improve defence against viral respiratory infections. We investigated whether a previous BCG vaccination is associated with less severe clinical progression of COVID-19 METHODS: A case-control study comparing the proportion with a BCG vaccine scar (indicating previous vaccination) in cases and controls presenting with COVID-19 to health units in Brazil. Cases were subjects with severe COVID-19 (O2 saturation < 90%, severe respiratory effort, severe pneumonia, severe acute respiratory syndrome, sepsis, and septic shock). Controls had COVID-19 not meeting the definition of “severe” above. Unconditional regression was used to estimate vaccine protection against clinical progression to severe disease, with strict control for age, comorbidity, sex, educational level, race/colour, and municipality. Internal matching and conditional regression were used for sensitivity analysis. RESULTS: BCG was associated with high protection against COVID-19 clinical progression, over 87% (95% CI 74–93%) in subjects aged 60 or less and 35% (95% CI − 44–71%) in older subjects. CONCLUSIONS: This protection may be relevant for public health in settings where COVID-19 vaccine coverage is still low and may have implications for research to identify vaccine candidates for COVID-19 that are broadly protective against mortality from future variants. Further research into the immunomodulatory effects of BCG may inform COVID-19 therapeutic research. BioMed Central 2023-04-13 /pmc/articles/PMC10099006/ /pubmed/37055776 http://dx.doi.org/10.1186/s12916-023-02859-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Pereira, Susan Martins
Barreto, Florisneide Rodrigues
de Souza, Ramon Andrade
de Souza Teles Santos, Carlos Antonio
Pereira, Marcos
da Paixão, Enny Santos
de Jesus Lima, Carla Cristina Oliveira
da Natividade, Marcio Santos
Lindoso, Ana Angélica Bulcão Portela
Fernandes, Eder Gatti
Junior, Evonio Barros Campelo
Pescarini, Julia Moreira
de Andrade, Kaio Vinicius Freitas
de Souza, Fernanda Mattos
de Britto, Elisangela Alves
Nunes, Ceuci
Ichihara, Maria Yuri
Dalcolmo, Margareth
Trajman, Anete
Barral-Netto, Manoel
Abubakar, Ibrahim
Barreto, Mauricio Lima
de Alencar Ximenes, Ricardo Arraes
Rodrigues, Laura Cunha
Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title_full Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title_fullStr Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title_full_unstemmed Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title_short Previous BCG vaccination is associated with less severe clinical progression of COVID-19
title_sort previous bcg vaccination is associated with less severe clinical progression of covid-19
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099006/
https://www.ncbi.nlm.nih.gov/pubmed/37055776
http://dx.doi.org/10.1186/s12916-023-02859-x
work_keys_str_mv AT pereirasusanmartins previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT barretoflorisneiderodrigues previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT desouzaramonandrade previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT desouzatelessantoscarlosantonio previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT pereiramarcos previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT dapaixaoennysantos previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT dejesuslimacarlacristinaoliveira previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT danatividademarciosantos previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT lindosoanaangelicabulcaoportela previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT fernandesedergatti previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT juniorevoniobarroscampelo previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT pescarinijuliamoreira previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT deandradekaioviniciusfreitas previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT desouzafernandamattos previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT debrittoelisangelaalves previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT nunesceuci previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT ichiharamariayuri previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT dalcolmomargareth previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT trajmananete previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT barralnettomanoel previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT abubakaribrahim previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT barretomauriciolima previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT dealencarximenesricardoarraes previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19
AT rodrigueslauracunha previousbcgvaccinationisassociatedwithlesssevereclinicalprogressionofcovid19